Management of HCV G4 Kasr Alainy

More documents

Recommendations

Info

Pariteprevir-ritonavir-Ombitasvir Asselah et al. Lancet Gastro Hep. 2016 Waked et al. Lancet Gastro Hep. 2016
SVR12 % SVR-12 % Pariteprevir-ritonavir-Ombitasvir Agate I: Results Agate II: Results 100 90 80 70 60 50 40 30 20 10 0 97 98 57 58 60 61 12 Weeks 16 Weeks 100 90 80 70 60 50 40 30 20 10 0 94 97 94 100 No cirrhosis 12 weeks 30 31 Compensated cirrhosis 12 weeks 93 27 29 Compensted cirrhosis 24 weeks Asselah et al. Lancet Gastro Hep. 2016 Waked et al. Lancet Gastro Hep. 2016
Page 2 and 3: Management of Patients with HCV Gen
Page 4 and 5: SVR12 (%) Sofosbuvir-RBV • 2 stud
Page 6 and 7: SVR12, % Sofosbuvir-Ledipasvir N=35
Page 8 and 9: SOF-RBV, SOF-LED, SOF-VEL • Integ
Page 10 and 11: SVR12 % Grazoprevir-Elbasvir EBR +
Page 12 and 13: SVR-12 % Sofosbuvir-Simeprevir •
Page 16 and 17: Pariteprevir-ritonavir-Ombitasvir A
Page 18 and 19: Gelcaprevir-Pibrentasvir (GP) Surve
Page 20 and 21: SVR 12 (%) Outcome of DAA Treatment
Page 22 and 23: http://www.hcvguidelines.org, acces
Page 24 and 25: EASL Recommendations 2016 Retreatme
Page 26 and 27: Conclusion • Treatment of HCV G4

Management of HCV G4 Kasr Alainy

Create successful ePaper yourself

Delete template?

Save as template?